{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:44:35Z","timestamp":1788799475677,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.3816\/clm.2009.n.082","type":"journal-article","created":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T02:02:24Z","timestamp":1262743344000},"page":"412-416","source":"Crossref","is-referenced-by-count":81,"title":["Evaluation of the Long-Term Tolerability and Clinical Benefit of Vorinostat in Patients With Advanced Cutaneous T-Cell Lymphoma"],"prefix":"10.3816","volume":"9","author":[{"given":"Madeleine","family":"Duvic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Breneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa R.","family":"Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sareeta","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"Vonderheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Abuav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Ricker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Boileau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gunchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Sanz-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa J.","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.n.082_bib1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","article-title":"Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides","volume":"19","author":"de Coninck","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.082_bib2","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.082_bib3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib4","author":"Cutaneous Lymphoma Foundation"},{"key":"10.3816\/CLM.2009.n.082_bib5","author":"The Leukemia & Lymphoma Society"},{"key":"10.3816\/CLM.2009.n.082_bib6","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0889-8588(03)00120-5","article-title":"The S\u00e9zary syndrome: hematologic criteria","volume":"17","author":"Vonderheid","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.3816\/CLM.2009.n.082_bib7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.082_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/mjd.2002.118538","article-title":"Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas","volume":"46","author":"Vonderheid","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib9","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and S\u00e9zary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib10","author":"NCCN"},{"key":"10.3816\/CLM.2009.n.082_bib11","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ctrv.2006.08.006","article-title":"Efficacy and tolerability of currently available therapies for the mycosis fungoides and S\u00e9zary syndrome variants of cutaneous T-cell lymphoma","volume":"33","author":"Whittaker","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.3816\/CLM.2009.n.082_bib12","first-page":"33","article-title":"Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies","volume":"21","author":"Duvic","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.3816\/CLM.2009.n.082_bib13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","article-title":"Treatment of cutaneous T cell lymphoma: current status and future directions","volume":"3","author":"Apisarnthanarax","year":"2002","journal-title":"Am J Clin Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib14","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1067\/mjd.2002.124607","article-title":"Optimizing bexarotene therapy for cutaneous T-cell lymphoma","volume":"47","author":"Talpur","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib15","first-page":"655","article-title":"Skin directed therapy for mycosis fungoides: a review","volume":"7","author":"Berthelot","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat Rev Cancer"},{"issue":"suppl 1","key":"10.3816\/CLM.2009.n.082_bib17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6603463","article-title":"Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor","volume":"95","author":"Richon","year":"2006","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2009.n.082_bib18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/PL00000896","article-title":"Histone acetylation and disease","volume":"58","author":"Timmermann","year":"2001","journal-title":"Cell Mol Life Sci"},{"key":"10.3816\/CLM.2009.n.082_bib19","first-page":"1422","article-title":"HDAC inhibitors for the treatment of cancer","volume":"4","author":"Secrist","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.3816\/CLM.2009.n.082_bib20","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"Glaser","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CLM.2009.n.082_bib21","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.3816\/CLM.2009.n.082_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-0609.2005.00470.x","article-title":"Developing new drugs for the treatment of lymphoma","volume":"66","author":"O'Connor","year":"2005","journal-title":"Eur J Haematol Suppl"},{"key":"10.3816\/CLM.2009.n.082_bib23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.0022-202X.2005.23925.x","article-title":"Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"125","author":"Zhang","year":"2005","journal-title":"J Invest Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","article-title":"Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer","volume":"26","author":"Blumenschein","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2009.n.082_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.082_bib26","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.n.082_bib27","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously","volume":"9","author":"Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.082_bib28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.082_bib29","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","article-title":"Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies","volume":"13","author":"Ramalingam","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.082_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.n.082_bib31","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1158\/1078-0432.CCR-06-1802","article-title":"A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat administered orally to patients with advanced cancer","volume":"12","author":"Rubin","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.n.082_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/dot.2007.43.9.1112980","article-title":"Vorinostat in cutaneous T-cell lymphoma","volume":"43","author":"Duvic","year":"2007","journal-title":"Drugs Today (Barc)"},{"key":"10.3816\/CLM.2009.n.082_bib33","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.n.082_bib34","first-page":"39","article-title":"Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma","volume":"2","author":"Duvic","year":"2008","journal-title":"Hematology Meeting Reports"},{"key":"10.3816\/CLM.2009.n.082_bib35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.2008.08612.x","article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","volume":"159","author":"Talpur","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.3816\/CLM.2009.n.082_bib36","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-07-6091","article-title":"Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma","volume":"68","author":"Fantin","year":"2008","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.n.082_bib37","unstructured":"Roth JA, Korenchuk S, Zhang T, et al. Mechanisms of in vitro acquired resistance to vorinostat (suberoylanilide hydroxamic acid, SAHA). Presented at: the 98th American Association of Cancer Research Annual Meeting; April 14-18, 2007; Los Angeles, CA; Abstract 694."},{"key":"10.3816\/CLM.2009.n.082_bib38","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ijc.21939","article-title":"The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L\/TRAIL","volume":"119","author":"Butler","year":"2006","journal-title":"Int J Cancer"},{"key":"10.3816\/CLM.2009.n.082_bib39","unstructured":"Bruzzese F, Rocco M, Leone A, et al. Synergistic antitumor interaction between histone deacetylase inhibitor vorinostat and topoisomerase I inhibitor topotecan in small cell lung cancer (SCLC) cells. Presented at: the 98th American Association of Cancer Research Annual Meeting; April 14-18, 2007; Los Angeles, CA; Abstract 701."}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011700312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,25]],"date-time":"2019-02-25T13:07:01Z","timestamp":1551100021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011700312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S1557919011700312"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.n.082","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}